Clinical Trial Update: Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial comparing higher dose Rituxan to standard dose Rituxan with CAVOP in immune thrombocytopenic purpura; results completed and posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Immune Thrombocytopenic Purpura | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-11-14